Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Bone Marrow Transplant

Retrieve available abstracts of 267 articles:
HTML format



Single Articles


    July 2021
  1. ZUCENKA A, Vaitekenaite V, Maneikis K, Davainis L, et al
    Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2021 Jul 17. pii: 10.1038/s41409-021-01416.
    PubMed     Abstract available


  2. KONUMA T, Kondo T, Masuko M, Shimizu H, et al
    Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission.
    Bone Marrow Transplant. 2021 Jul 16. pii: 10.1038/s41409-021-01409.
    PubMed     Abstract available


  3. GREIL C, Engelhardt M, Ihorst G, Duque-Afonso J, et al
    Correction to: Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2021 Jul 8. pii: 10.1038/s41409-021-01366.
    PubMed    


    June 2021
  4. GEVA M, Pryce A, Shouval R, Fein JA, et al
    High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2021 Jun 29. pii: 10.1038/s41409-021-01377.
    PubMed     Abstract available


  5. CHO BS, Min GJ, Park SS, Park S, et al
    Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11.
    Bone Marrow Transplant. 2021 Jun 28. pii: 10.1038/s41409-021-01384.
    PubMed     Abstract available


  6. SHIMOMURA Y, Hara M, Hirabayashi S, Kondo T, et al
    Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.
    Bone Marrow Transplant. 2021 Jun 21. pii: 10.1038/s41409-021-01380.
    PubMed    


  7. BRUZZESE A, Assanto GM, Diverio D, Quattrocchi L, et al
    Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience.
    Bone Marrow Transplant. 2021;56:1455-1457.
    PubMed    


    May 2021
  8. WAIDHAUSER J, Labopin M, Esteve J, Kroger N, et al
    Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT.
    Bone Marrow Transplant. 2021 May 31. pii: 10.1038/s41409-021-01322.
    PubMed     Abstract available


  9. PERCIVAL ME, Wang HL, Zhang MJ, Saber W, et al
    Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2021 May 20. pii: 10.1038/s41409-021-01353.
    PubMed    


  10. BEAUVERD Y, Morin S, Stephan C, De Ramon Ortiz C, et al
    The EBMT Cytogenetic Risk Score maintains its prognostic significance in acute myeloid leukemia following allogeneic stem cell transplantation in a cohort with 40% of patients transplanted with in vitro partial T-cell depleted graft.
    Bone Marrow Transplant. 2021 May 18. pii: 10.1038/s41409-021-01334.
    PubMed    


  11. KANAAN SB, Delaney C, Milano F, Scaradavou A, et al
    Cord blood maternal microchimerism following unrelated cord blood transplantation.
    Bone Marrow Transplant. 2021;56:1090-1098.
    PubMed     Abstract available


  12. QIAN CS, Ma X, Wang J, Wang TJ, et al
    PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation.
    Bone Marrow Transplant. 2021;56:1003-1005.
    PubMed    


    April 2021
  13. KHARFAN-DABAJA MA, Labopin M, Bazarbachi A, Ciceri F, et al
    Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT.
    Bone Marrow Transplant. 2021 Apr 30. pii: 10.1038/s41409-021-01317.
    PubMed     Abstract available


  14. TOYODA K, Yasunaga JI, Choi I, Suehiro Y, et al
    The HTLV-1 proviral status is a potential prognostic biomarker for adult T-cell leukemia-lymphoma treated with allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2021 Apr 29. pii: 10.1038/s41409-021-01311.
    PubMed    


  15. RAGON BK
    FLT3-ITDos and FLT3-ITDon'ts: navigating maintenance therapy in FLT3-ITD-positive acute myeloid leukemia following stem cell transplantation.
    Bone Marrow Transplant. 2021 Apr 28. pii: 10.1038/s41409-021-01269.
    PubMed    


  16. PERCIVAL ME, Wang HL, Zhang MJ, Saber W, et al
    Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2021 Apr 16. pii: 10.1038/s41409-021-01261.
    PubMed     Abstract available


  17. BADAR T, Szabo A, Litzow M, Burkart M, et al
    Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data.
    Bone Marrow Transplant. 2021 Apr 6. pii: 10.1038/s41409-021-01279.
    PubMed     Abstract available


  18. CHO H, Kim Y, Yoon JH, Lee J, et al
    Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2021 Apr 6. pii: 10.1038/s41409-021-01253.
    PubMed     Abstract available


    March 2021
  19. KOLLER P, Saliba RM, Ledesma C, Rondon G, et al
    Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2021 Mar 25. pii: 10.1038/s41409-021-01262.
    PubMed    


  20. DAHER-REYES G, Kim T, Novitzky-Basso I, Kim KH, et al
    Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Bone Marrow Transplant. 2021 Mar 25. pii: 10.1038/s41409-021-01255.
    PubMed     Abstract available


  21. SHARMA A, Li Y, Huang S, Talleur AC, et al
    Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS.
    Bone Marrow Transplant. 2021 Mar 19. pii: 10.1038/s41409-021-01267.
    PubMed     Abstract available


  22. VERSLUYS AB, Boelens JJ, Pronk C, Lankester A, et al
    Correction: Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens.
    Bone Marrow Transplant. 2021 Mar 15. pii: 10.1038/s41409-021-01257.
    PubMed    


  23. SAKAGUCHI H, Miyamura T, Tomizawa D, Taga T, et al
    Effect of extramedullary disease on allogeneic hematopoietic cell transplantation for pediatric acute myeloid leukemia: a nationwide retrospective study.
    Bone Marrow Transplant. 2021 Mar 10. pii: 10.1038/s41409-021-01250.
    PubMed     Abstract available


  24. WILLIAMS L, Doucette K, Karp JE, Lai C, et al
    Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.
    Bone Marrow Transplant. 2021 Mar 8. pii: 10.1038/s41409-021-01214.
    PubMed     Abstract available


  25. YANADA M
    The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia.
    Bone Marrow Transplant. 2021 Mar 8. pii: 10.1038/s41409-021-01247.
    PubMed     Abstract available


  26. RUGGERI A, Labopin M, Angelucci E, Blaise D, et al
    Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT.
    Bone Marrow Transplant. 2021 Mar 5. pii: 10.1038/s41409-021-01248.
    PubMed     Abstract available


    February 2021
  27. TANG X, Valdez BC, Ma Y, Zhang Q, et al
    Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2021 Feb 26. pii: 10.1038/s41409-021-01238.
    PubMed     Abstract available


  28. QU C, Song Y, Yin J, Ma Y, et al
    Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations.
    Bone Marrow Transplant. 2021 Feb 24. pii: 10.1038/s41409-021-01230.
    PubMed    


  29. DUNAIKINA M, Zhekhovtsova Z, Shelikhova L, Glushkova S, et al
    Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of alphabeta T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia.
    Bone Marrow Transplant. 2021 Feb 16. pii: 10.1038/s41409-021-01232.
    PubMed     Abstract available


  30. CHRISTOPEIT M, Reichard M, Niederwieser C, Massoud R, et al
    Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection.
    Bone Marrow Transplant. 2021 Feb 9. pii: 10.1038/s41409-021-01225.
    PubMed    


  31. PAUTAS C, Raffoux E, Lambert J, Legrand O, et al
    Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia.
    Bone Marrow Transplant. 2021 Feb 9. pii: 10.1038/s41409-020-01207.
    PubMed     Abstract available


  32. RAUTENBERG C, Bergmann A, Pechtel S, Fischermanns C, et al
    Wilm's Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation.
    Bone Marrow Transplant. 2021;56:442-450.
    PubMed     Abstract available


  33. DEYA-MARTINEZ A, Alonso-Saladrigues A, Garcia AP, Faura A, et al
    Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia.
    Bone Marrow Transplant. 2021;56:376-386.
    PubMed     Abstract available


    January 2021
  34. VERSLUYS AB, Boelens JJ, Pronk C, Lankester A, et al
    Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens.
    Bone Marrow Transplant. 2021 Jan 19. pii: 10.1038/s41409-020-01201.
    PubMed     Abstract available


  35. LOPEZ R, Plat G, Bertrand Y, Ducassou S, et al
    Testosterone deficiency in men surviving childhood acute leukemia after treatment with hematopoietic stem cell transplantation or testicular radiation: an L.E.A. study.
    Bone Marrow Transplant. 2021 Jan 16. pii: 10.1038/s41409-020-01180.
    PubMed     Abstract available


  36. NAKASONE H, Kako S, Mori T, Takahashi S, et al
    Stopping tyrosine kinase inhibitors started after allogeneic HCT in patients with Philadelphia chromosome-positive leukemia.
    Bone Marrow Transplant. 2021 Jan 8. pii: 10.1038/s41409-020-01206.
    PubMed     Abstract available


  37. YOKOYAMA H, Kanda J, Kawahara Y, Uchida N, et al
    Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation.
    Bone Marrow Transplant. 2021 Jan 8. pii: 10.1038/s41409-020-01203.
    PubMed     Abstract available


    December 2020
  38. SANZ J, Labopin M, Sanz MA, Aljurf M, et al
    Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission.
    Bone Marrow Transplant. 2020 Dec 15. pii: 10.1038/s41409-020-01162.
    PubMed     Abstract available


  39. HIRSCHBUHL K, Labopin M, Houhou M, Gabellier L, et al
    Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
    Bone Marrow Transplant. 2020 Dec 9. pii: 10.1038/s41409-020-01173.
    PubMed     Abstract available


  40. MAZIARZ RT, Levis M, Patnaik MM, Scott BL, et al
    Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.
    Bone Marrow Transplant. 2020 Dec 7. pii: 10.1038/s41409-020-01153.
    PubMed     Abstract available


  41. AHN JS, Kim T, Jung SH, Ahn SY, et al
    Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing.
    Bone Marrow Transplant. 2020 Dec 5. pii: 10.1038/s41409-020-01165.
    PubMed     Abstract available


  42. YANADA M, Konuma T, Yamasaki S, Kondo T, et al
    Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes.
    Bone Marrow Transplant. 2020 Dec 2. pii: 10.1038/s41409-020-01163.
    PubMed     Abstract available


    November 2020
  43. PAVIGLIANITI A, Labopin M, Blaise D, Socie G, et al
    Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT.
    Bone Marrow Transplant. 2020 Nov 28. pii: 10.1038/s41409-020-01155.
    PubMed     Abstract available


  44. GIEBEL S, Labopin M, Socie G, Beauvais D, et al
    Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2020 Nov 25. pii: 10.1038/s41409-020-01139.
    PubMed     Abstract available


  45. HUA J, Zhang J, Zhang X, Wu X, et al
    Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2020 Nov 24. pii: 10.1038/s41409-020-01140.
    PubMed     Abstract available


  46. JENTZSCH M, Grimm J, Bill M, Brauer D, et al
    ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2020 Nov 19. pii: 10.1038/s41409-020-01129.
    PubMed     Abstract available


  47. BAZARBACHI AH, Al Hamed R, Labopin M, Halaburda K, et al
    Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party.
    Bone Marrow Transplant. 2020 Nov 18. pii: 10.1038/s41409-020-01135.
    PubMed     Abstract available


  48. KANG HM, Kim SK, Lee JW, Chung NG, et al
    Efficacy of low dose antithymocyte globulin on overall survival, relapse rate, and infectious complications following allogeneic peripheral blood stem cell transplantation for leukemia in children.
    Bone Marrow Transplant. 2020 Nov 17. pii: 10.1038/s41409-020-01121.
    PubMed     Abstract available


    October 2020
  49. GREIL C, Engelhardt M, Ihorst G, Duque-Afonso J, et al
    Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2020 Oct 31. pii: 10.1038/s41409-020-01101.
    PubMed     Abstract available


  50. YOON JH, Min GJ, Park SS, Park S, et al
    Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission.
    Bone Marrow Transplant. 2020 Oct 30. pii: 10.1038/s41409-020-01097.
    PubMed     Abstract available


  51. YANG L, Tan Y, Shi J, Zhao Y, et al
    Prophylactic modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: a matched-pair analysis.
    Bone Marrow Transplant. 2020 Oct 19. pii: 10.1038/s41409-020-01088.
    PubMed     Abstract available


  52. BAZARBACHI A, Labopin M, Blaise D, Forcade E, et al
    Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
    Bone Marrow Transplant. 2020 Oct 6. pii: 10.1038/s41409-020-01074.
    PubMed     Abstract available


  53. SCHETELIG J, Chevallier P, van Gelder M, Hoek J, et al
    Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.
    Bone Marrow Transplant. 2020 Oct 2. pii: 10.1038/s41409-020-01069.
    PubMed     Abstract available


  54. LOKE J, Labopin M, Craddock C, Niederwieser D, et al
    Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT.
    Bone Marrow Transplant. 2020 Oct 2. pii: 10.1038/s41409-020-01072.
    PubMed     Abstract available


    September 2020
  55. SAGLIO F, Berger M, Spadea M, Pessolano R, et al
    Haploidentical HSCT with post transplantation cyclophosphamide versus unrelated donor HSCT in pediatric patients affected by acute leukemia.
    Bone Marrow Transplant. 2020 Sep 23. pii: 10.1038/s41409-020-01063.
    PubMed     Abstract available


  56. DI CRISTANZIANO V, Meyer-Schwickerath C, Eberhardt KA, Rybniker J, et al
    Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia.
    Bone Marrow Transplant. 2020 Sep 18. pii: 10.1038/s41409-020-01059.
    PubMed    


  57. ZAMPERLINI-NETTO G, Fernandes JF, Garcia JL, Ribeiro AAF, et al
    COVID-19 after hematopoietic stem cell transplantation: report of two children.
    Bone Marrow Transplant. 2020 Sep 16. pii: 10.1038/s41409-020-01041.
    PubMed    


  58. GIEBEL S, Labopin M, Sobczyk-Kruszelnicka M, Stelljes M, et al
    Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the
    Bone Marrow Transplant. 2020 Sep 5. pii: 10.1038/s41409-020-01050.
    PubMed     Abstract available


  59. JIANG S, Fan Y, Fang Y, Hou C, et al
    The role of EVI1 gene quantification in AML patients with 11q23/MLL rearrangement after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2020 Sep 5. pii: 10.1038/s41409-020-01048.
    PubMed     Abstract available


  60. BARON F, Labopin M, Blaise D, Itala-Remes M, et al
    Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT.
    Bone Marrow Transplant. 2020 Sep 4. pii: 10.1038/s41409-020-01051.
    PubMed     Abstract available


    August 2020
  61. MURANUSHI H, Shindo T, Hishizawa M, Tokunaga M, et al
    Correction: GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2020 Aug 25. pii: 10.1038/s41409-020-01037.
    PubMed     Abstract available


  62. LU X, Tang LV, Wang HF, You Y, et al
    The great challenge of managing recipients of hematopoietic stem cell transplantation combined with COVID-19.
    Bone Marrow Transplant. 2020 Aug 25. pii: 10.1038/s41409-020-01035.
    PubMed    


  63. SCHETELIG J, Hoek J, Stilgenbauer S, Middeke JM, et al
    Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study.
    Bone Marrow Transplant. 2020 Aug 16. pii: 10.1038/s41409-020-01013.
    PubMed    


  64. YANADA M, Konuma T, Mizuno S, Saburi M, et al
    Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia.
    Bone Marrow Transplant. 2020 Aug 14. pii: 10.1038/s41409-020-01032.
    PubMed     Abstract available


  65. KAWAHARA Y, Morimoto A, Inagaki J, Koh K, et al
    Unrelated cord blood transplantation with myeloablative conditioning for pediatric acute lymphoblastic leukemia in remission: prognostic factors.
    Bone Marrow Transplant. 2020 Aug 11. pii: 10.1038/s41409-020-01019.
    PubMed     Abstract available


  66. FUJIMOTO A, Ishida F, Izutsu K, Yamasaki S, et al
    Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia.
    Bone Marrow Transplant. 2020 Aug 10. pii: 10.1038/s41409-020-01009.
    PubMed     Abstract available


  67. EL-HARASIS MA, Hefazi M, Julakanti R, Hogan WJ, et al
    Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Bone Marrow Transplant. 2020 Aug 8. pii: 10.1038/s41409-020-01021.
    PubMed    


  68. MCCAUGHAN G, Ma D, Moore J
    Two cases of successful autologous stem cell transplantation in patients with multiple myeloma and concurrent chronic myeloid leukaemia.
    Bone Marrow Transplant. 2020 Aug 8. pii: 10.1038/s41409-020-01025.
    PubMed    


  69. NAJIMA Y, Sadato D, Harada Y, Oboki K, et al
    Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT.
    Bone Marrow Transplant. 2020 Aug 5. pii: 10.1038/s41409-020-01016.
    PubMed     Abstract available


  70. DALLE JH, Balduzzi A, Bader P, Pieczonka A, et al
    The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG.
    Bone Marrow Transplant. 2020 Aug 4. pii: 10.1038/s41409-020-01014.
    PubMed     Abstract available


  71. SHI J, Cao L, Luo Y, Zhao Y, et al
    Maintenance sorafenib is superior to prophylactic donor lymphocyte infusion at improving the prognosis of acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2020 Aug 4. pii: 10.1038/s41409-020-01015.
    PubMed    


    July 2020
  72. MIZUNO S, Yanada M, Kawamura K, Masuko M, et al
    Allogeneic hematopoietic cell transplantation efficacy in patients with Philadelphia chromosome-positive acute myeloid leukemia in complete remission.
    Bone Marrow Transplant. 2020 Jul 31. pii: 10.1038/s41409-020-01011.
    PubMed     Abstract available


  73. NAGLER A, Baron F, Labopin M, Polge E, et al
    Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT.
    Bone Marrow Transplant. 2020 Jul 28. pii: 10.1038/s41409-020-01005.
    PubMed     Abstract available


  74. MURANUSHI H, Shindo T, Hishizawa M, Tokunaga M, et al
    GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2020 Jul 14. pii: 10.1038/s41409-020-00996.
    PubMed     Abstract available


  75. DEBUREAUX PE, Sicre de Fontbrune F, Bonfim C, Dalle JH, et al
    FLAG-sequential regimen followed by bone marrow transplantation for myelodysplastic syndrome or acute leukemia in patients with Fanconi anemia: a Franco-Brazilian study.
    Bone Marrow Transplant. 2020 Jul 10. pii: 10.1038/s41409-020-0994.
    PubMed    


    June 2020
  76. FRIETSCH JJ, Hunstig F, Wittke C, Junghanss C, et al
    Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity.
    Bone Marrow Transplant. 2020 Jun 30. pii: 10.1038/s41409-020-0984.
    PubMed     Abstract available


  77. GU B, Shi BY, Zhang X, Zhou SY, et al
    Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells.
    Bone Marrow Transplant. 2020 Jun 24. pii: 10.1038/s41409-020-0982.
    PubMed     Abstract available


  78. NAGLER A, Dholaria B, Labopin M, Bruno B, et al
    The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study.
    Bone Marrow Transplant. 2020 Jun 19. pii: 10.1038/s41409-020-0974.
    PubMed     Abstract available


  79. NIU A, McDougal A, Ning B, Safa F, et al
    COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma.
    Bone Marrow Transplant. 2020 Jun 15. pii: 10.1038/s41409-020-0972.
    PubMed    


  80. BRISSOT E, Labopin M, Baron F, Bazarbachi A, et al
    Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2020 Jun 11. pii: 10.1038/s41409-020-0970.
    PubMed    


  81. VAN ENS D, Mousset CM, Hutten TJA, van der Waart AB, et al
    PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity.
    Bone Marrow Transplant. 2020 Jun 11. pii: 10.1038/s41409-020-0966.
    PubMed     Abstract available


  82. NUNEZ-TORRON C, Garcia-Gutierrez V, Tenorio-Nunez MC, Moreno-Jimenez G, et al
    Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19.
    Bone Marrow Transplant. 2020 Jun 4. pii: 10.1038/s41409-020-0961.
    PubMed    


    May 2020
  83. AKAHOSHI Y, Nishiwaki S, Arai Y, Harada K, et al
    Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukem
    Bone Marrow Transplant. 2020 May 23. pii: 10.1038/s41409-020-0951.
    PubMed     Abstract available


  84. SHOUVAL R, Labopin M, Bomze D, Baerlocher GM, et al
    Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission.
    Bone Marrow Transplant. 2020 May 10. pii: 10.1038/s41409-020-0936.
    PubMed     Abstract available


  85. ROBESOVA B, Drncova M, Folta A, Krejci M, et al
    Donor-derived DNA variability in fingernails of acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation detected by direct PCR.
    Bone Marrow Transplant. 2020 May 9. pii: 10.1038/s41409-020-0938.
    PubMed    


  86. COOPERRIDER JH, Fulton N, Artz AS, Larson RA, et al
    Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome.
    Bone Marrow Transplant. 2020 May 6. pii: 10.1038/s41409-020-0925.
    PubMed    


  87. REES MJ, Spencer A, Browett P, Alvaro F, et al
    High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission.
    Bone Marrow Transplant. 2020 May 6. pii: 10.1038/s41409-020-0924.
    PubMed    


  88. PERIC Z, Labopin M, Peczynski C, Polge E, et al
    Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT.
    Bone Marrow Transplant. 2020 May 2. pii: 10.1038/s41409-020-0878.
    PubMed     Abstract available


    March 2020
  89. YANADA M, Fukuda T, Tanaka M, Ota S, et al
    Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data.
    Bone Marrow Transplant. 2020 Mar 20. pii: 10.1038/s41409-020-0868.
    PubMed     Abstract available


  90. ROVIRA M, Villamor N, Cobo F, Fernandez-Aviles F, et al
    Is chronic lymphocytic leukemia curable? A clinical case relapsing 21 years after allogeneic stem-cell transplantation.
    Bone Marrow Transplant. 2020 Mar 20. pii: 10.1038/s41409-020-0861.
    PubMed    


  91. BRISSOT E, Labopin M, Russo D, Martin S, et al
    Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party.
    Bone Marrow Transplant. 2020 Mar 17. pii: 10.1038/s41409-020-0849.
    PubMed     Abstract available


  92. TERAKURA S, Nishida T, Sawa M, Kato T, et al
    Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome.
    Bone Marrow Transplant. 2020 Mar 16. pii: 10.1038/s41409-020-0859.
    PubMed     Abstract available


  93. YAMASHITA T, Takami A, Uchida N, Fukuda T, et al
    Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.
    Bone Marrow Transplant. 2020 Mar 12. pii: 10.1038/s41409-020-0856.
    PubMed     Abstract available


  94. KANDA J, Umeda K, Kato K, Murata M, et al
    Effect of graft-versus-host disease on outcomes after pediatric single cord blood transplantation.
    Bone Marrow Transplant. 2020 Mar 11. pii: 10.1038/s41409-020-0853.
    PubMed     Abstract available


  95. SPYRIDONIDIS A, Labopin M, Savani BN, Niittyvuopio R, et al
    Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.
    Bone Marrow Transplant. 2020 Mar 6. pii: 10.1038/s41409-020-0835.
    PubMed     Abstract available


    February 2020
  96. KAITO S, Najima Y, Harada K, Fukuda T, et al
    Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia harboring t(1;19)(q23;p13.3); comparison with normal karyotype.
    Bone Marrow Transplant. 2020 Feb 10. pii: 10.1038/s41409-020-0816.
    PubMed     Abstract available


    January 2020
  97. JIN A, Feng J, Wei G, Wu W, et al
    CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations.
    Bone Marrow Transplant. 2020 Jan 31. pii: 10.1038/s41409-020-0807.
    PubMed     Abstract available


  98. WETHMAR K, Matern S, Esseling E, Angenendt L, et al
    Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia.
    Bone Marrow Transplant. 2020 Jan 30. pii: 10.1038/s41409-020-0801.
    PubMed     Abstract available


  99. SPYRIDONIDIS A, Labopin M, Savani BN, Niittyvuopio R, et al
    Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.
    Bone Marrow Transplant. 2020 Jan 29. pii: 10.1038/s41409-020-0803.
    PubMed     Abstract available


  100. SAGLIO F, Zecca M, Pagliara D, Giorgiani G, et al
    Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retro
    Bone Marrow Transplant. 2020 Jan 29. pii: 10.1038/s41409-020-0806.
    PubMed     Abstract available


  101. ALTOURI S, Allan D, Atkins H, Fulcher J, et al
    Total body irradiation (18 Gy) without chemotherapy as conditioning for allogeneic hematopoietic cell transplantation in refractory acute myeloid leukemia.
    Bone Marrow Transplant. 2020 Jan 28. pii: 10.1038/s41409-020-0799.
    PubMed    


  102. ROTULO GA, Beaupain B, Rialland F, Paillard C, et al
    HSCT may lower leukemia risk in ELANE neutropenia: a before-after study from the French Severe Congenital Neutropenia Registry.
    Bone Marrow Transplant. 2020 Jan 28. pii: 10.1038/s41409-020-0800.
    PubMed     Abstract available


    December 2019
  103. ZHANG H, Hu Y, Wei G, Wu W, et al
    Successful chimeric antigen receptor T cells therapy in extramedullary relapses of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2019 Dec 17. pii: 10.1038/s41409-019-0778.
    PubMed    


  104. SULA M, Bacher U, Oppliger Leibundgut E, Mansouri Taleghani B, et al
    Excellent outcome after consolidation with autologous transplantation in patients with core binding factor acute myeloid leukemia.
    Bone Marrow Transplant. 2019 Dec 3. pii: 10.1038/s41409-019-0762.
    PubMed    


    November 2019
  105. SIDHARTHAN N, Fuchs E, Unni M, Mony U, et al
    HLA-mismatched microtransplantation for relapsed or refractory acute myeloid leukemia as a bridge to allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2019 Nov 29. pii: 10.1038/s41409-019-0761.
    PubMed    


  106. MICHALLET M, Dreger P, Sobh M, Koster L, et al
    Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia.
    Bone Marrow Transplant. 2019 Nov 7. pii: 10.1038/s41409-019-0742.
    PubMed     Abstract available


  107. HOFFMANN AP, Besch AL, Othus M, Morsink LM, et al
    Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
    Bone Marrow Transplant. 2019 Nov 4. pii: 10.1038/s41409-019-0739.
    PubMed    


    October 2019
  108. DETEIX C, Mesnil F, Furst S, Milpied N, et al
    Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor.
    Bone Marrow Transplant. 2019 Oct 29. pii: 10.1038/s41409-019-0722.
    PubMed     Abstract available


  109. HEINICKE T, Labopin M, Polge E, Niederwieser D, et al
    Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (>/=60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.
    Bone Marrow Transplant. 2019 Oct 23. pii: 10.1038/s41409-019-0720.
    PubMed     Abstract available


  110. YOON SY, Yoon JH, Min GJ, Park SS, et al
    Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2019 Oct 7. pii: 10.1038/s41409-019-0708.
    PubMed    


    September 2019
  111. BAZARBACHI AH, Al Hamed R, Labopin M, Afanasyev B, et al
    Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party.
    Bone Marrow Transplant. 2019 Sep 27. pii: 10.1038/s41409-019-0702.
    PubMed     Abstract available


  112. DEBUREAUX PE, Labopin M, Mamez AC, Lapusan S, et al
    Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia.
    Bone Marrow Transplant. 2019 Sep 25. pii: 10.1038/s41409-019-0690.
    PubMed     Abstract available


  113. BASQUIERA AL, Berro M, Yantorno S, Castro M, et al
    Haploidentical transplant in adult patients with acute lymphoblastic leukemia in Argentina: a comparison with matched related and unrelated donors.
    Bone Marrow Transplant. 2019 Sep 24. pii: 10.1038/s41409-019-0687.
    PubMed     Abstract available


  114. TACHIBANA T, Ishizaki T, Takahashi S, Najima Y, et al
    Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis.
    Bone Marrow Transplant. 2019 Sep 19. pii: 10.1038/s41409-019-0689.
    PubMed    


  115. TOMORI S, Morishima S, Nishi Y, Nakachi S, et al
    Transplant-related complications are impediments to the success of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia patients in non-complete remission.
    Bone Marrow Transplant. 2019 Sep 18. pii: 10.1038/s41409-019-0669.
    PubMed     Abstract available


  116. MA Y, Qu C, Dai H, Yin J, et al
    Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia.
    Bone Marrow Transplant. 2019 Sep 18. pii: 10.1038/s41409-019-0677.
    PubMed    


  117. AMBERGE S, Kramer M, Schrottner P, Heidrich K, et al
    Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome.
    Bone Marrow Transplant. 2019 Sep 18. pii: 10.1038/s41409-019-0678.
    PubMed     Abstract available


  118. GATWOOD KS, Labopin M, Savani BN, Finke J, et al
    Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study.
    Bone Marrow Transplant. 2019 Sep 16. pii: 10.1038/s41409-019-0673.
    PubMed     Abstract available


  119. SOLOMON SR, Solh M, Jackson KC, Zhang X, et al
    Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program.
    Bone Marrow Transplant. 2019 Sep 16. pii: 10.1038/s41409-019-0675.
    PubMed     Abstract available


  120. XU J, Zhao R, Yang L, Gong H, et al
    Haploidentical stem cells combined with a small dose of umbilical cord blood transplantation exert similar survival outcome of HLA-matched stem cells transplantation in T-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2019 Sep 5. pii: 10.1038/s41409-019-0666.
    PubMed    


  121. EL FAKIH R, Kotb A, Hashmi S, Chaudhri N, et al
    Outcomes of allogeneic hematopoietic cell transplant for acute myeloid leukemia in adolescent patients.
    Bone Marrow Transplant. 2019 Sep 5. pii: 10.1038/s41409-019-0667.
    PubMed     Abstract available


  122. SHADMAN M, Maloney DG, Storer B, Sandmaier BM, et al
    Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.
    Bone Marrow Transplant. 2019 Sep 3. pii: 10.1038/s41409-019-0660.
    PubMed     Abstract available


    August 2019
  123. STYCZYNSKI J, Tridello G, Koster L, Iacobelli S, et al
    Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors.
    Bone Marrow Transplant. 2019 Aug 27. pii: 10.1038/s41409-019-0624.
    PubMed     Abstract available


  124. WANG X, Hu Y, Liu X, Yu J, et al
    Quantitative characterization of T-cell repertoire alteration in Chinese patients with B-cell acute lymphocyte leukemia after CAR-T therapy.
    Bone Marrow Transplant. 2019 Aug 5. pii: 10.1038/s41409-019-0625.
    PubMed     Abstract available


  125. PIERINI A, Ruggeri L, Carotti A, Falzetti F, et al
    The "ultimate" haploidentical transplantation for the elderly with high-risk acute myeloid leukemia.
    Bone Marrow Transplant. 2019;54.
    PubMed    


  126. SCHLEGEL P, Jung G, Lang AM, Doring M, et al
    ADCC can improve graft vs leukemia effect after T- and B-cell depleted haploidentical stem cell transplantation in pediatric B-lineage ALL.
    Bone Marrow Transplant. 2019;54.
    PubMed     Abstract available


  127. EINSELE H, Rasche L, Topp MS, Martin Kortum K, et al
    The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT.
    Bone Marrow Transplant. 2019;54.
    PubMed     Abstract available


  128. PIERINI A, Ruggeri L, Mancusi A, Carotti A, et al
    T cell depletion and no post transplant immune suppression allow separation of graft versus leukemia from graft versus host disease.
    Bone Marrow Transplant. 2019;54.
    PubMed     Abstract available


  129. JACOBY E
    The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2019;54.
    PubMed     Abstract available


  130. NAGLER A, Ruggeri A
    Haploidentical stem cell transplantation (HaploSCT) for patients with acute leukemia-an update on behalf of the ALWP of the EBMT.
    Bone Marrow Transplant. 2019;54.
    PubMed     Abstract available


    June 2019
  131. MOUKALLED NM, Kharfan-Dabaja MA
    What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia?
    Bone Marrow Transplant. 2019 Jun 3. pii: 10.1038/s41409-019-0584.
    PubMed     Abstract available


    May 2019
  132. YANO S, Yokoyama H, Yanada M, Mori J, et al
    Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission.
    Bone Marrow Transplant. 2019 May 31. pii: 10.1038/s41409-019-0571.
    PubMed     Abstract available


  133. RUGGERI A, Labopin M, Savani B, Paviglianiti A, et al
    Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT.
    Bone Marrow Transplant. 2019 May 31. pii: 10.1038/s41409-019-0582.
    PubMed     Abstract available


  134. KANSAGRA AJ, Frey NV, Bar M, Laetsch TW, et al
    Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transp
    Bone Marrow Transplant. 2019 May 15. pii: 10.1038/s41409-019-0451.
    PubMed     Abstract available


  135. GUILLAUME T, Malard F, Magro L, Labopin M, et al
    Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Bone Marrow Transplant. 2019 May 14. pii: 10.1038/s41409-019-0536.
    PubMed     Abstract available


  136. ALDOSS I, Nakamura R, Yang D, Salhotra A, et al
    Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia.
    Bone Marrow Transplant. 2019 May 14. pii: 10.1038/s41409-019-0553.
    PubMed    


  137. BABOR F, Peters C, Manser AR, Glogova E, et al
    Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL.
    Bone Marrow Transplant. 2019 May 14. pii: 10.1038/s41409-019-0543.
    PubMed     Abstract available


  138. YANADA M, Konuma T, Kuwatsuka Y, Kondo T, et al
    Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience.
    Bone Marrow Transplant. 2019 May 8. pii: 10.1038/s41409-019-0539.
    PubMed     Abstract available


    April 2019
  139. MASCHAN M, Shelikhova L, Ilushina M, Shekhovtsova Z, et al
    Outcome of alphabeta T cell-depleted transplantation in children with high-risk acute myeloid leukemia, grafted in remission.
    Bone Marrow Transplant. 2019 Apr 15. pii: 10.1038/s41409-019-0531.
    PubMed    


  140. YAMASAKI S, Aoki J, Mori J, Mizuno S, et al
    Better disease control before allogeneic stem cell transplantation is crucial to improve the outcomes of transplantation for acute myeloid leukemia patients with extramedullary disease.
    Bone Marrow Transplant. 2019 Apr 10. pii: 10.1038/s41409-019-0527.
    PubMed    


  141. LUBKING A, Dreimane A, Sandin F, Isaksson C, et al
    Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.
    Bone Marrow Transplant. 2019 Apr 8. pii: 10.1038/s41409-019-0513.
    PubMed     Abstract available


    February 2019
  142. GODWIN CD, Fromm JR, Othus M, Sandmaier BM, et al
    Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission.
    Bone Marrow Transplant. 2019 Feb 25. pii: 10.1038/s41409-019-0481.
    PubMed    


  143. OKAMOTO Y, Kudo K, Tabuchi K, Tomizawa D, et al
    Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia.
    Bone Marrow Transplant. 2019 Feb 4. pii: 10.1038/s41409-019-0461.
    PubMed     Abstract available


  144. BATTIPAGLIA G, Boumendil A, Labopin M, Ciceri F, et al
    Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT.
    Bone Marrow Transplant. 2019 Feb 4. pii: 10.1038/s41409-019-0459.
    PubMed     Abstract available


  145. INOUE Y, Endo S, Matsuno N, Kikukawa Y, et al
    Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2019;54:338-342.
    PubMed    


  146. ZHANG YY, Mo XD, Zhang XH, Xu LP, et al
    FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients.
    Bone Marrow Transplant. 2019 Feb 1. pii: 10.1038/s41409-019-0456.
    PubMed     Abstract available


    January 2019
  147. DAHLBERG A, Leisenring W, Bleakley M, Meshinchi S, et al
    Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children.
    Bone Marrow Transplant. 2019 Jan 22. pii: 10.1038/s41409-019-0438.
    PubMed     Abstract available


  148. FUJI S, Yamaguchi T, Inoue Y, Utsunomiya A, et al
    VCAP-AMP-VECP as a preferable induction chemotherapy in transplant-eligible patients with aggressive adult T-cell leukemia-lymphoma: a propensity score analysis.
    Bone Marrow Transplant. 2019 Jan 21. pii: 10.1038/s41409-019-0446.
    PubMed     Abstract available


  149. WIKTOR-JEDRZEJCZAK W, Drozd-Sokolowska J, Eikema DJ, Hoek J, et al
    EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).
    Bone Marrow Transplant. 2019 Jan 21. pii: 10.1038/s41409-019-0448.
    PubMed     Abstract available


  150. HAMILTON BK, Rybicki L, Hirsch C, Przychodzen B, et al
    Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.
    Bone Marrow Transplant. 2019 Jan 17. pii: 10.1038/s41409-019-0444.
    PubMed     Abstract available


  151. QU C, Li Z, Kang L, Wang Y, et al
    Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells.
    Bone Marrow Transplant. 2019 Jan 10. pii: 10.1038/s41409-018-0423.
    PubMed    


  152. SEITZ CM, Eyrich M, Greil J, Schlegel P, et al
    Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts.
    Bone Marrow Transplant. 2019;54:53-62.
    PubMed     Abstract available


    December 2018
  153. YOSHIMITSU M, Utsunomiya A, Fuji S, Fujiwara H, et al
    A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma.
    Bone Marrow Transplant. 2018 Dec 13. pii: 10.1038/s41409-018-0400.
    PubMed     Abstract available


  154. ASSI R, Mahfouz R, Owen R, Gunthorpe M, et al
    PAX5, NOTCH3, CBFB, and ACD drive an activated RAS pathway and monosomy 7 to B-ALL and AML in donor cell leukemia.
    Bone Marrow Transplant. 2018 Dec 10. pii: 10.1038/s41409-018-0419.
    PubMed    


  155. ALATRASH G, Kidwell KM, Thall PF, Di Stasi A, et al
    Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.
    Bone Marrow Transplant. 2018 Dec 10. pii: 10.1038/s41409-018-0405.
    PubMed     Abstract available


  156. BONDANZA A, Ruggeri L, Noviello M, Eikema DJ, et al
    Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting.
    Bone Marrow Transplant. 2018 Dec 7. pii: 10.1038/s41409-018-0351.
    PubMed     Abstract available


  157. SUN W, Mo XD, Zhang XH, Xu LP, et al
    Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients.
    Bone Marrow Transplant. 2018 Dec 5. pii: 10.1038/s41409-018-0406.
    PubMed     Abstract available


  158. HU Y, Wang J, Wei G, Yu J, et al
    A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2018 Dec 5. pii: 10.1038/s41409-018-0403.
    PubMed     Abstract available


    November 2018
  159. GRIMM J, Bill M, Jentzsch M, Beinicke S, et al
    Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation.
    Bone Marrow Transplant. 2018 Nov 30. pii: 10.1038/s41409-018-0413.
    PubMed     Abstract available


  160. ALDOSS I, Pullarkat V
    Indications for allogeneic hematopoietic cell transplantation for adults with Philadelphia-chromosome negative acute lymphoblastic leukemia in first complete remission: all about MRD?
    Bone Marrow Transplant. 2018 Nov 16. pii: 10.1038/s41409-018-0398.
    PubMed    


  161. GOWDA L, Shah M, Badar I, Bashir Q, et al
    Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.
    Bone Marrow Transplant. 2018 Nov 16. pii: 10.1038/s41409-018-0392.
    PubMed     Abstract available


  162. KIM HJ, Sohn HJ, Hong JA, Lee HJ, et al
    Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I/II trial.
    Bone Marrow Transplant. 2018 Nov 8. pii: 10.1038/s41409-018-0383.
    PubMed    


  163. GERULL S, Tschan-Plessl A, Mathew R, Nair G, et al
    Late relapse after stopping sorafenib in allogeneic hematopoietic stem cell transplant recipients.
    Bone Marrow Transplant. 2018 Nov 6. pii: 10.1038/s41409-018-0376.
    PubMed    


  164. GIEBEL S, Marks DI, Boissel N, Baron F, et al
    Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute L
    Bone Marrow Transplant. 2018 Nov 1. pii: 10.1038/s41409-018-0373.
    PubMed     Abstract available


    October 2018
  165. ZHANG WP, Wang ZW, Hu XX, Chen J, et al
    Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study.
    Bone Marrow Transplant. 2018 Oct 19. pii: 10.1038/s41409-018-0356.
    PubMed     Abstract available


  166. SHAH MV, Saliba RM, Rondon G, Chen J, et al
    Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2018 Oct 18. pii: 10.1038/s41409-018-0367.
    PubMed     Abstract available


  167. MOUKALLED NM, El Darsa H, Haibe Y, Massoud R, et al
    Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation.
    Bone Marrow Transplant. 2018 Oct 4. pii: 10.1038/s41409-018-0347.
    PubMed    


  168. PINGEL J, Wang T, Hagenlocher Y, Hernandez-Frederick CJ, et al
    The effect of NIMA matching in adult unrelated mismatched hematopoietic stem cell transplantation - a joint study of the Acute Leukemia Working Party of the EBMT and the CIBMTR.
    Bone Marrow Transplant. 2018 Oct 2. pii: 10.1038/s41409-018-0345.
    PubMed     Abstract available


    September 2018
  169. KONGTIM P, Parmar S, Milton DR, Perez JMR, et al
    Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Bone Marrow Transplant. 2018 Sep 26. pii: 10.1038/s41409-018-0344.
    PubMed     Abstract available


    August 2018
  170. LIN RJ, Elko TA, Perales MA, Alexander K, et al
    End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center.
    Bone Marrow Transplant. 2018 Aug 22. pii: 10.1038/s41409-018-0311.
    PubMed     Abstract available


  171. KANELLOPOULOS A, Kaparou M, Xenou E, Paneesha S, et al
    Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplantat in HIV-infected patient with acute myeloid leukaemia.
    Bone Marrow Transplant. 2018 Aug 16. pii: 10.1038/s41409-018-0297.
    PubMed     Abstract available


  172. GUNES G, Goker H, Demiroglu H, Malkan UY, et al
    Extramedullary relapses of acute leukemias after allogeneic hematopoietic stem cell transplantation: clinical features, cumulative incidence, and risk factors.
    Bone Marrow Transplant. 2018 Aug 16. pii: 10.1038/s41409-018-0303.
    PubMed     Abstract available


  173. YANADA M, Masuko M, Mori J, Aoki J, et al
    Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades.
    Bone Marrow Transplant. 2018 Aug 14. pii: 10.1038/s41409-018-0301.
    PubMed     Abstract available


  174. DABAS R, Dharmani-Khan P, Modi M, Van Slyke T, et al
    Anti-thymocyte globulin's activity against acute myeloid leukemia stem cells.
    Bone Marrow Transplant. 2018 Aug 14. pii: 10.1038/s41409-018-0296.
    PubMed     Abstract available


  175. LEE CJ, Savani BN, Mohty M, Gorin NC, et al
    Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Tran
    Bone Marrow Transplant. 2018 Aug 13. pii: 10.1038/s41409-018-0286.
    PubMed     Abstract available


  176. SHETH V, Labopin M, Canaani J, Volin L, et al
    Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.
    Bone Marrow Transplant. 2018 Aug 7. pii: 10.1038/s41409-018-0288.
    PubMed     Abstract available


    July 2018
  177. HIRANO M, Jimbo K, Ogawa M, Ochi K, et al
    Chronic inflammatory demyelinating polyneuropathy in adult T-cell leukemia-lymphoma patients following allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2018 Jul 23. pii: 10.1038/s41409-018-0202.
    PubMed    


  178. SAITO A, Nishikawa T, Oyoshi T, Nakagawa S, et al
    Giant radiation-induced cavernous haemangioma before reduced-intensity bone marrow transplantation for acute lymphoblastic leukaemia.
    Bone Marrow Transplant. 2018 Jul 23. pii: 10.1038/s41409-018-0272.
    PubMed    


    June 2018
  179. TOMIZAWA D, Yoshida M, Kondo T, Miyamura T, et al
    Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive cases.
    Bone Marrow Transplant. 2018 Jun 29. pii: 10.1038/s41409-018-0273.
    PubMed     Abstract available


  180. TANG S, Shen H, Qu C, Dai H, et al
    Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Bone Marrow Transplant. 2018 Jun 25. pii: 10.1038/s41409-018-0249.
    PubMed     Abstract available


  181. GABELLI M, Zecca M, Messina C, Carraro E, et al
    Hematopoietic stem cell transplantation for isolated extramedullary relapse of acute lymphoblastic leukemia in children.
    Bone Marrow Transplant. 2018 Jun 13. pii: 10.1038/s41409-018-0259.
    PubMed     Abstract available


  182. HOCHBERG J, Zahler S, Geyer MB, Chen N, et al
    The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leuke
    Bone Marrow Transplant. 2018 Jun 13. pii: 10.1038/s41409-018-0247.
    PubMed     Abstract available


  183. FUJI S, Inoue Y, Utsunomiya A, Moriuchi Y, et al
    Impact of pretransplant central nervous system invasion in patients with aggressive adult T-cell leukemia lymphoma.
    Bone Marrow Transplant. 2018 Jun 13. pii: 10.1038/s41409-018-0248.
    PubMed    


  184. BONDA A, Punatar S, Gokarn A, Mohite A, et al
    Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?
    Bone Marrow Transplant. 2018 Jun 8. pii: 10.1038/s41409-018-0222.
    PubMed    


    May 2018
  185. CRADDOCK C, Hoelzer D, Komanduri KV
    Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia.
    Bone Marrow Transplant. 2018 May 31. pii: 10.1038/s41409-018-0203.
    PubMed     Abstract available


  186. KATO M, Kurata M, Kanda J, Kato K, et al
    Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia.
    Bone Marrow Transplant. 2018 May 24. pii: 10.1038/s41409-018-0221.
    PubMed     Abstract available


  187. TKACZYK ER, Chen F, Wang J, Gandelman JS, et al
    Overcoming human disagreement assessing erythematous lesion severity on 3D photos of chronic graft-versus-host disease.
    Bone Marrow Transplant. 2018 May 8. pii: 10.1038/s41409-018-0211.
    PubMed    


  188. LINDEMANN M, Eiz-Vesper B, Steckel NK, Tischer S, et al
    Adoptive transfer of cellular immunity against cytomegalovirus by virus-specific lymphocytes from a third-party family donor.
    Bone Marrow Transplant. 2018 May 8. pii: 10.1038/s41409-018-0209.
    PubMed    


  189. DREGER P, Michallet M, Bosman P, Dietrich S, et al
    Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
    Bone Marrow Transplant. 2018 May 4. pii: 10.1038/s41409-018-0207.
    PubMed     Abstract available


    April 2018
  190. YANG L, Tan Y, Shi J, Zhao Y, et al
    Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma.
    Bone Marrow Transplant. 2018 Apr 30. pii: 10.1038/s41409-018-0184.
    PubMed    


  191. BROWNBACK KR, Pitts LR, Abhyankar S
    Safety of nintedanib for treatment of fibrotic lung disease after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2018 Apr 26. pii: 10.1038/s41409-018-0182.
    PubMed    


  192. HALABURDA K, Labopin M, Houhou M, Niederwieser D, et al
    AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation.
    Bone Marrow Transplant. 2018 Apr 18. pii: 10.1038/s41409-018-0165.
    PubMed     Abstract available


  193. BATTIPAGLIA G, Ruggeri A, Labopin M, Volin L, et al
    Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia.
    Bone Marrow Transplant. 2018 Apr 16. pii: 10.1038/s41409-018-0169.
    PubMed     Abstract available


    March 2018
  194. BHATT VR, Chen B, Gyawali B, Lee SJ, et al
    Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia.
    Bone Marrow Transplant. 2018 Mar 27. pii: 10.1038/s41409-018-0164.
    PubMed     Abstract available


  195. CASTAGNOLA E, Bagnasco F, Menoni S, Muraca M, et al
    Risk factors associated with development and mortality by invasive fungal diseases in pediatric allogeneic stem cell transplantation. A pediatric subgroup analysis of data from a prospective study of the Gruppo Italiano Trapianto di Midollo Osseo (GIT
    Bone Marrow Transplant. 2018 Mar 21. pii: 10.1038/s41409-018-0160.
    PubMed    


  196. GAAFAR A, Sheereen A, Almohareb F, Eldali A, et al
    Prognostic role of KIR genes and HLA-C after hematopoietic stem cell transplantation in a patient cohort with acute myeloid leukemia from a consanguineous community.
    Bone Marrow Transplant. 2018 Mar 16. pii: 10.1038/s41409-018-0123.
    PubMed     Abstract available


  197. GASSAS A, Sivaprakasam P, Cummins M, Breslin P, et al
    High transplant-related mortality associated with haematopoietic stem cell transplantation for paediatric therapy-related acute myeloid leukaemia (t-AML). A study on behalf of the United Kingdom Paediatric Blood and Bone Marrow Transplant Group.
    Bone Marrow Transplant. 2018 Mar 15. pii: 10.1038/s41409-018-0157.
    PubMed     Abstract available


  198. MARKEY KA, Gartlan KH, Kuns RD, Lane SW, et al
    Conventional dendritic cells are required for the cross-presentation of leukemia-specific antigen in a model of AML relapse post-BMT.
    Bone Marrow Transplant. 2018 Mar 13. pii: 10.1038/s41409-018-0148.
    PubMed    


  199. INOUE Y, Fuji S, Tanosaki R, Inamoto Y, et al
    Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma.
    Bone Marrow Transplant. 2018 Mar 9. pii: 10.1038/s41409-018-0139.
    PubMed     Abstract available


  200. CHENG Z, Zhou L, Hu K, Dai Y, et al
    Prognostic significance of microRNA-99a in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2018 Mar 7. pii: 10.1038/s41409-018-0146.
    PubMed     Abstract available


    February 2018
  201. OCHI K, Fuji S, Takano K, Tajima K, et al
    The putative anti-leukemic effects of anti-thymocyte globulins in patients with CD7-positive acute myeloid leukemia.
    Bone Marrow Transplant. 2018 Feb 19. pii: 10.1038/s41409-018-0115.
    PubMed     Abstract available


  202. BHATT VR, Chen B, Lee SJ
    Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: A National Cancer Database Study.
    Bone Marrow Transplant. 2018 Feb 5. pii: 10.1038/s41409-018-0105.
    PubMed     Abstract available


  203. ZHANG Q, Zhou Y, Majaw JK, Xu J, et al
    Acute appendicitis in leukaemia patients undergoing haematopoietic stem cell transplantation during the neutropaenic phase: a case series from a single BMT centre in China.
    Bone Marrow Transplant. 2018;53:219-222.
    PubMed    


  204. RASHIDI A, Linden MA, Percival ME, Sandmaier BM, et al
    Recommendations for reporting post-transplant relapse in AML.
    Bone Marrow Transplant. 2018;53:111-113.
    PubMed    


    January 2018
  205. FUJI S, Kurosawa S, Inamoto Y, Murata T, et al
    Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis.
    Bone Marrow Transplant. 2018 Jan 25. pii: 10.1038/s41409-017-0082.
    PubMed    


  206. ALHASHIM N, Aljurf M, Hassanein M, Chaudhri N, et al
    Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia: clinical characteristics, incidence, risk factors and outcomes.
    Bone Marrow Transplant. 2018 Jan 25. pii: 10.1038/s41409-018-0093.
    PubMed     Abstract available


  207. LAHOUD OB, Moskowitz AJ, Horwitz SM, Giralt SA, et al
    Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma.
    Bone Marrow Transplant. 2018 Jan 22. pii: 10.1038/s41409-017-0086.
    PubMed    


  208. AMRO ELSHOURY, Wallace PK, Borowitz MJ, Kader A, et al
    BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2018 Jan 17. pii: 10.1038/s41409-017-0036.
    PubMed    


  209. CESARO S, Crocchiolo R, Tridello G, Knelange N, et al
    Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT.
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0016.
    PubMed     Abstract available


  210. OGAWA H, Ikegame K, Daimon T, Uchida N, et al
    Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR.
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0028.
    PubMed    


  211. JIANG Z, Jia J, Yue C, Pang Y, et al
    Haploidentical hematopoietic SCT using helical tomotherapy for total-body irradiation and targeted dose boost in patients with high-risk/refractory acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0049.
    PubMed     Abstract available


  212. DEVILLIER R, Labopin M, Chevallier P, Ledoux MP, et al
    Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Ma
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0043.
    PubMed     Abstract available


  213. WAIS V, Kundgen L, Bohl SR, von Harsdorf S, et al
    Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.
    Bone Marrow Transplant. 2018;53:94-96.
    PubMed    


    December 2017
  214. MILONE G, Sacchi N, Gallina A, Leotta S, et al
    Access to alternative donor hematopoietic search and transplantation for acute leukemia in different macro-regions of Italy. A GITMO/IBMDR study.
    Bone Marrow Transplant. 2017 Dec 21. pii: 10.1038/s41409-017-0026.
    PubMed     Abstract available


  215. GADALLA SM, Wang T, Loftus D, Friedman L, et al
    No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia.
    Bone Marrow Transplant. 2017 Dec 21. pii: 10.1038/s41409-017-0029.
    PubMed     Abstract available


  216. KETTERL TG, Wu D, Fromm JR, Soma L, et al
    Donor derived T-cell large granular lymphocyte leukemia after cord blood transplant for pediatric T-cell lymphoblastic leukemia.
    Bone Marrow Transplant. 2017 Dec 21. pii: 10.1038/s41409-017-0037.
    PubMed    


  217. VAN GORKOM G, van Gelder M, Eikema DJ, Blok HJ, et al
    Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT.
    Bone Marrow Transplant. 2017 Dec 18. pii: 10.1038/s41409-017-0023.
    PubMed     Abstract available


    October 2017
  218. CHO C, Hsu M, Barba P, Maloy MA, et al
    Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
    Bone Marrow Transplant. 2017 Oct 9. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


  219. HEMMATI PG, Pfeifer K, Vuong LG, Jehn CF, et al
    Allogeneic stem cell transplantation for non-de novo AML or advanced myelodysplastic syndromes: influence of GvHD and donor lymphocyte infusions on long-term outcome.
    Bone Marrow Transplant. 2017 Oct 9. doi: 10.1038/bmt.2017.
    PubMed    


    September 2017
  220. SCHEID C, de Wreede L, van Biezen A, Koenecke C, et al
    Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.
    Bone Marrow Transplant. 2017 Sep 11. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


  221. KORDELAS L, Buttkereit U, Lindemann M, Koldehoff M, et al
    alphabeta-T-cell depleted donor lymphocyte infusion for leukemia relapse after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2017 Sep 4. doi: 10.1038/bmt.2017.
    PubMed    


  222. MODI D, Deol A, Kim S, Ayash L, et al
    Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.
    Bone Marrow Transplant. 2017 Sep 4. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


    August 2017
  223. FREEMAN AT, Stover AM, Grover NS, Shea TC, et al
    Patient perspectives on physical function after allogeneic hematopoietic stem cell transplantation: a qualitative study.
    Bone Marrow Transplant. 2017 Aug 7. doi: 10.1038/bmt.2017.
    PubMed    


  224. LAHTEENMAKI K, Wacklin P, Taskinen M, Tuovinen E, et al
    Haematopoietic stem cell transplantation induces severe dysbiosis in intestinal microbiota of paediatric ALL patients.
    Bone Marrow Transplant. 2017 Aug 7. doi: 10.1038/bmt.2017.
    PubMed    


    July 2017
  225. GEETHAKUMARI PR, Leiby B, Nair R, Alpdogan SO, et al
    Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome.
    Bone Marrow Transplant. 2017 Jul 31. doi: 10.1038/bmt.2017.
    PubMed    


  226. FERGUSON P, Craddock C
    Allogeneic transplantation in primary refractory AML.
    Bone Marrow Transplant. 2017;52:950-951.
    PubMed    


    June 2017
  227. NGUYEN S, Achour A, Souchet L, Vigouroux S, et al
    Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Societe Francaise de Gref
    Bone Marrow Transplant. 2017 Jun 26. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


  228. TERAKURA S, Kuwatsuka Y, Yamasaki S, Wake A, et al
    GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia.
    Bone Marrow Transplant. 2017 Jun 12. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


  229. ZHANG R, Shi W, Wang HF, You Y, et al
    Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


  230. LITZOW MR, Fielding AK, Luger SM, Paietta E, et al
    The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


  231. GROS FX, Cazaubiel T, Forcade E, Lechevalier N, et al
    Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed    


  232. SALEM R, Massoud R, Haffar B, Mahfouz R, et al
    Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed    


  233. VAN DE PEPPEL RJ, von dem Borne PA, le Cessie S, de Boer MGJ, et al
    A new time-dependent approach for assessment of the impact of invasive aspergillosis shows effect on short- but not on long-term survival of patients with AML or high-risk MDS.
    Bone Marrow Transplant. 2017;52:883-888.
    PubMed     Abstract available


    May 2017
  234. JETHAVA YS, Sica S, Savani B, Socola F, et al
    Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.
    Bone Marrow Transplant. 2017 May 15. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


    April 2017
  235. YU J, Hu Y, Pu C, Liang Z, et al
    Successful chimeric Ag receptor modified T cell therapy for isolated testicular relapse after hematopoietic cell transplantation in an acute lymphoblastic leukemia patient.
    Bone Marrow Transplant. 2017 Apr 24. doi: 10.1038/bmt.2017.
    PubMed    


  236. SIMONIN M, Dalissier A, Labopin M, Willasch A, et al
    More chronic GvHD and non-relapse mortality after peripheral blood stem cell compared with bone marrow in hematopoietic transplantation for paediatric acute lymphoblastic leukemia: a retrospective study on behalf of the EBMT Paediatric Diseases Workin
    Bone Marrow Transplant. 2017 Apr 10. doi: 10.1038/bmt.2017.
    PubMed    


  237. YAMASAKI S, Suzuki R, Hatano K, Fukushima K, et al
    Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


  238. GARNIER A, Guillaume T, Peterlin P, Bene MC, et al
    Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed    


  239. BILL M, Jentzsch M, Grimm J, Schubert K, et al
    Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed    


  240. SELLNER L, Bruggemann M, Schlitt M, Knecht H, et al
    GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.
    Bone Marrow Transplant. 2017;52:656.
    PubMed    


  241. SCHETELIG J, de Wreede LC, van Gelder M, Andersen NS, et al
    Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2017;52:552-560.
    PubMed     Abstract available


  242. ANDERSSON BS, Thall PF, Valdez BC, Milton DR, et al
    Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.
    Bone Marrow Transplant. 2017;52:580-587.
    PubMed     Abstract available


    March 2017
  243. TERAKURA S, Wake A, Inamoto Y, Murata M, et al
    Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil.
    Bone Marrow Transplant. 2017;52:423-430.
    PubMed     Abstract available


  244. VAN GELDER M, de Wreede LC, Bornhauser M, Niederwieser D, et al
    Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2017;52:372-380.
    PubMed     Abstract available


  245. ANTAR A, Otrock ZK, El-Cheikh J, Kharfan-Dabaja MA, et al
    Inhibition of FLT3 in AML: a focus on sorafenib.
    Bone Marrow Transplant. 2017;52:344-351.
    PubMed     Abstract available


    February 2017
  246. BLUM V, Heini AD, Novak U, Taleghani BM, et al
    Hematopoietic stem cell remobilization with vinorelbine and filgrastim in AML.
    Bone Marrow Transplant. 2017 Feb 13. doi: 10.1038/bmt.2017.
    PubMed    


  247. YAMASHITA T, Ikegame K, Kojima H, Tanaka H, et al
    Effective desensitization of donor-specific HLA antibodies using platelet transfusion bearing targeted HLA in a case of HLA-mismatched allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2017 Feb 6. doi: 10.1038/bmt.2017.
    PubMed    


  248. EDER S, Labopin M, Finke J, Bunjes D, et al
    Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT.
    Bone Marrow Transplant. 2017;52:238-244.
    PubMed     Abstract available


    January 2017
  249. DULERY R, Nibourel O, Gauthier J, Elsermans V, et al
    Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Abstract available


  250. CARRE M, Thiebaut-Bertrand A, Larrat S, Leroy V, et al
    Fatal autochthonous fulminant hepatitis E early after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed    


  251. KHOURI IF, Sui D, Jabbour EJ, Samuels BI, et al
    Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.
    Bone Marrow Transplant. 2017;52:28-33.
    PubMed     Abstract available


  252. ZHENG CC, Zhu XY, Tang BL, Zhang XH, et al
    Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML.
    Bone Marrow Transplant. 2017;52:88-94.
    PubMed     Abstract available


    December 2016
  253. LEGRAND F, Le Floch AC, Granata A, Furst S, et al
    Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed    


    November 2016
  254. ALBRING JC, Inselmann S, Sauer T, Schliemann C, et al
    PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2016 Nov 28. doi: 10.1038/bmt.2016.
    PubMed    


    September 2016
  255. SARACENI F, Bruno B, Lemoli RM, Meloni G, et al
    Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission.
    Bone Marrow Transplant. 2016 Sep 26. doi: 10.1038/bmt.2016.
    PubMed    


  256. WILLASCH AM, Salzmann-Manrique E, Krenn T, Duerken M, et al
    Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience.
    Bone Marrow Transplant. 2016 Sep 19. doi: 10.1038/bmt.2016.
    PubMed     Abstract available


  257. GATTI-MAYS ME, Manion M, Bowen LN, Brown GT, et al
    Toxoplasmosis encephalitis with immune-reconstitution inflammatory syndrome in an allogeneic stem cell transplant patient: a case report.
    Bone Marrow Transplant. 2016 Sep 19. doi: 10.1038/bmt.2016.
    PubMed    


  258. PHILLIPS EH, Hodson A, Hermine O, Bazarbachi A, et al
    Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant?
    Bone Marrow Transplant. 2016 Sep 12. doi: 10.1038/bmt.2016.
    PubMed     Abstract available


    August 2016
  259. O'DONNELL PV, Eapen M, Horowitz MM, Logan BR, et al
    Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis.
    Bone Marrow Transplant. 2016 Aug 15. doi: 10.1038/bmt.2016.
    PubMed    


    July 2016
  260. MAGENAU J, Westervelt P, Khaled S, McGuirk J, et al
    A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2016 Jul 18. doi: 10.1038/bmt.2016.
    PubMed     Abstract available


  261. EHRLICH KB, Miller GE, Scheide T, Baveja S, et al
    Pre-transplant emotional support is associated with longer survival after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2016 Jul 18. doi: 10.1038/bmt.2016.
    PubMed     Abstract available


    June 2016
  262. TSIRIGOTIS P, Byrne M, Schmid C, Baron F, et al
    Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.
    Bone Marrow Transplant. 2016 Jun 13. doi: 10.1038/bmt.2016.
    PubMed     Abstract available


  263. POHLEN M, Groth C, Sauer T, Gorlich D, et al
    Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (60 years).
    Bone Marrow Transplant. 2016 Jun 13. doi: 10.1038/bmt.2016.
    PubMed     Abstract available


    May 2016
  264. KRUGER P, Cooney J, Nivison-Smith I, Dodds A, et al
    All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand.
    Bone Marrow Transplant. 2016 May 23. doi: 10.1038/bmt.2016.
    PubMed    


  265. LAM W, Viswabandya A, Hussain S, Messner HA, et al
    A unique case of tuberculosis dissemination presenting as cutaneous lesions in a post allogeneic stem cell transplant patient.
    Bone Marrow Transplant. 2016 May 16. doi: 10.1038/bmt.2016.
    PubMed    


  266. RASHIDI A, DiPersio JF, Westervelt P, Abboud CN, et al
    HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2016 May 9. doi: 10.1038/bmt.2016.
    PubMed    


    April 2016
  267. RAMANATHAN M, Teira P, Battiwalla M, Barrett J, et al
    Impact of early CMV reactivation in cord blood stem cell recipients in the current era.
    Bone Marrow Transplant. 2016 Apr 4. doi: 10.1038/bmt.2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: